
Oncoinvent hits recruitment milestone in ovarian cancer trial
Fifty-four patients have now enrolled in Oncoinvent’s Phase 2 study of Radspherin, a radiopharmaceutical therapy designed to eliminate residual cancer cells in the abdominal cavity. This achievement marks the halfway point for the trial, which aims to improve outcomes for patients battling peritoneal metastases following surgical resection.
























